Anemia

AMAG Pharmaceuticals Attains FDA Acceptance on Supplemental Drug Application for Anemia Treatment

Feraheme now can be indicated to treat iron-deficient patients who previously could not take oral iron treatments.

AMAG Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration has accepted for review the company’s supplemental new drug application for Feraheme Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012. The sNDA requests FDA approval to expand the indication for ferumoxytol beyond the current indication for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to adult patients with IDA who have failed or could not take oral iron treatment.

No votes yet

Medgenics Granted Patent for Sustained Delivery of Anemia Treatment

The Biopump is intended to provide safe, sustained delivery of erythropoietin for anemia patients.

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics’ EPODURE Biopump technology for delivery of erythropoietin (EPO). Medgenics is developing EPODURE to address the need for safer, sustained treatment of anemia.

No votes yet
Syndicate content